PMID- 18551111
OWN - NLM
STAT- MEDLINE
DCOM- 20090305
LR  - 20240109
IS  - 1930-7381 (Print)
IS  - 1930-7381 (Linking)
VI  - 16
IP  - 9
DP  - 2008 Sep
TI  - Quercetin ameliorates metabolic syndrome and improves the inflammatory status in 
      obese Zucker rats.
PG  - 2081-7
LID - 10.1038/oby.2008.315 [doi]
AB  - The aim of this study was to analyze the effects of chronic administration of 
      high doses of quercetin on metabolic syndrome abnormalities, including obesity, 
      dyslipidemia, hypertension, and insulin resistance. For this purpose, obese 
      Zucker rats and their lean littermates were used. The rats received a daily dose 
      of quercetin (2 or 10 mg/kg of body weight) or vehicle for 10 weeks. Body weight 
      and systolic blood pressure (SBP) were recorded weekly. At the end of the 
      treatment, plasma concentrations of triglycerides, total cholesterol, free-fatty 
      acids (FFAs), glucose, insulin, adiponectin, and nitrate plus nitrite (NOx) were 
      determined. Tumor necrosis factor-alpha (TNF-alpha) production, inducible nitric 
      oxide synthase (iNOS), and endothelial nitric oxide synthase (eNOS) protein 
      expression were analyzed in visceral adipose tissue (VAT). The raised SBP and 
      high plasma concentrations of triglycerides, total cholesterol, FFA, and insulin 
      found in obese Zucker rats were reduced in obese rats that received either of the 
      doses of quercetin assayed. The higher dose also improved the inflammatory status 
      peculiar to this model, as it increased the plasma concentration of adiponectin, 
      reduced NOx levels in plasma, and lowered VAT TNF-alpha production in obese 
      Zucker rats. Furthermore, chronic intake of the higher dose of quercetin enhanced 
      VAT eNOS expression among obese Zucker rats, whereas it downregulated VAT iNOS 
      expression. In conclusion, both doses of quercetin improved dyslipidemia, 
      hypertension, and hyperinsulinemia in obese Zucker rats, but only the high dose 
      produced antiinflammatory effects in VAT together with a reduction in body weight 
      gain.
FAU - Rivera, Leonor
AU  - Rivera L
AD  - Department of Pharmacology, CIBER-EHD, School of Pharmacy, University of Granada, 
      Granada, Spain.
FAU - Moron, Rocio
AU  - Moron R
FAU - Sanchez, Manuel
AU  - Sanchez M
FAU - Zarzuelo, Antonio
AU  - Zarzuelo A
FAU - Galisteo, Milagros
AU  - Galisteo M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Obesity (Silver Spring)
JT  - Obesity (Silver Spring, Md.)
JID - 101264860
RN  - 0 (Adiponectin)
RN  - 0 (Antioxidants)
RN  - 0 (Blood Glucose)
RN  - 0 (Fatty Acids, Nonesterified)
RN  - 0 (Insulin)
RN  - 0 (Triglycerides)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 9IKM0I5T1E (Quercetin)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type II)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Adiponectin/blood
MH  - Adipose Tissue/*drug effects/enzymology/pathology
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Blood Glucose/metabolism
MH  - Blood Pressure/drug effects
MH  - Body Weight/drug effects
MH  - Eating/drug effects
MH  - Fatty Acids, Nonesterified/blood
MH  - Insulin/blood
MH  - Male
MH  - Metabolic Syndrome/*drug therapy/metabolism/pathology
MH  - Nitric Oxide/blood
MH  - Nitric Oxide Synthase Type II/biosynthesis
MH  - Nitric Oxide Synthase Type III/biosynthesis
MH  - Obesity/*drug therapy/metabolism/pathology
MH  - Quercetin/*pharmacology
MH  - Rats
MH  - Rats, Zucker
MH  - Triglycerides/blood
MH  - Tumor Necrosis Factor-alpha/biosynthesis
EDAT- 2008/06/14 09:00
MHDA- 2009/03/06 09:00
CRDT- 2008/06/14 09:00
PHST- 2008/06/14 09:00 [pubmed]
PHST- 2009/03/06 09:00 [medline]
PHST- 2008/06/14 09:00 [entrez]
AID - oby2008315 [pii]
AID - 10.1038/oby.2008.315 [doi]
PST - ppublish
SO  - Obesity (Silver Spring). 2008 Sep;16(9):2081-7. doi: 10.1038/oby.2008.315.